In last week's "Who's Buying Now?," Coley Pharmaceutical
One Coley partner, Inside Value pick Pfizer
Coley also has a major collaboration with Sanofi-Aventis
With a projected $70 million in cash left at the end of the year, and a burn rate of $35 million to $39 million for 2007, the two phase 3 clinical cancer trials with Pfizer will be Coley's next major milestones. In addition, look for more licensing deals over the next year, especially for the promising VaxImmune.
I like Coley at its current $230 million market cap, given the company's strong partnerships and the phase 3 trials' near-term potential. With solid phase 2 results showing a greater (but not statistically significant) median survival rate, I believe that PF-3512676 has a good chance for success in phase 3.
For more Foolish biotech coverage, check out the market-beating Rule Breakers newsletter service, which finds innovators of all stripes and types. See all our recommendations and get access to message boards and exclusive content with a 30-day free trial.
Fool contributor Mike Havrilla, R.Ph., B.S., Pharm.D., is a Rite Aid pharmacist who lives, writes, works, and enjoys running on the streets and trails in the small Pennsylvania town of Portage. He invites your comments and feedback. See his stock picks and pans for free on Motley Fool CAPS. Mike does not have a position in any company mentioned in this article. The Fool has a disclosure policy.